1. Ahn, S.M., Cha, J.Y., Kim, J., Kim, D., Trang, H.T., Kim, Y.M., Cho, Y.H., Park, D. & Hong, S. (2012) Smad3 regulates E-cadherin via miRNA-200 pathway. Oncogene, 31, 3051-3059.
2. Bai, W.D., Ye, X.M., Zhang, M.Y., Zhu, H.Y., Xi, W.J., Huang, X., Zhao, J., Gu, B., Zheng, G.X., Yang, A.G. & Jia, L.T. (2014) MiR-200c suppresses TGF-beta signaling and counteracts trastuzumab resistance and metastasis by targeting ZNF217 and ZEB1 in breast cancer. Int. J. Cancer, 135, 1356-1368.
3. Cao, L., Wang, J. & Wang, P.Q. (2016) MiR-326 is a diagnostic biomarker and regulates cell survival and apoptosis by targeting Bcl-2 in osteosarcoma. Biomed. Pharmacother., 84, 828-835.
4. Cao, Y., Liu, Y., Ping, F., Yi, L., Zeng, Z. & Li, Y. (2018) miR-200b/c attenuates lipopolysaccharide-induced early pulmonary fibrosis by targeting ZEB1/2 via p38 MAPK and TGF-beta/smad3 signaling pathways. Lab. Invest., 98, 339-359.
5. Chang, L., Yuan, Y., Li, C., Guo, T., Qi, H., Xiao, Y., Dong, X., Liu, Z. & Liu, Q. (2016) Upregulation of SNHG6 regulates ZEB1 expression by competitively binding miR-101-3p and interacting with UPF1 in hepatocellular carcinoma. Cancer Lett., 383, 183-194.